Imaging Ductal Carcinoma In Situ in the Era of De-Escalation: Role, Limits, and Clinical Implications for Risk-Adapted Management

The widespread implementation of population-based mammographic screening has markedly increased the detection of ductal carcinoma in situ (DCIS), without a proportional reduction in breast cancer-specific mortality. This divergence has intensified concerns regarding overdiagnosis and overtreatment and has prompted increasing interest in treatment de-escalation and active surveillance strategies. Breast imaging remains indispensable for DCIS detection, extent assessment, and longitudinal monitoring. However, although imaging features correlate with histopathologic risk factors at the population level, their ability to predict individual biological progression is inherently probabilistic and limited. Overinterpretation of imaging phenotypes as surrogates of invasive destiny risks inappropriate reassurance or unjustified therapeutic escalation, particularly in the context of high-sensitivity modalities that may overestimate disease extent or trigger additional interventions without proven outcome benefits. This review examines the modality-specific roles of mammography, ultrasound, breast magnetic resonance imaging (MRI), contrast-enhanced mammography (CEM), and emerging artificial intelligence (AI) approaches within contemporary DCIS management, with particular attention to their implementation in active surveillance trials such as LORIS, COMET, LORD, and LORETTA. Across modalities, imaging primarily reflects lesion morphology, spatial distribution, and vascular behaviour, and functions most reliably as a risk-filtering and safety-gating instrument aimed at excluding radiologically unsafe scenarios, including occult invasion, underestimated disease extent, or imaging evolution incompatible with continued observation. By delineating both the capabilities and the epistemological limits of imaging, this review proposes a structured clinical decision framework in which imaging supports-but does not independently determine-risk-adapted management. Disciplined integration of imaging into multidisciplinary decision-making is essential to enable safe de-escalation, prevent false reassurance, and align DCIS care with patient-centred and value-based principles.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-03-05
DOI
https://doi.org/10.3390/diagnostics16050776
Primary Topic
MRI in cancer diagnosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Imaging Ductal Carcinoma In Situ in the Era of De-Escalation: Role, Limits, and Clinical Implications for Risk-Adapted Management

Francesca Caumo, Gianluca Gatta, Lanfranco Musto, Marcella Buono et al.
Diagnostics
MRI in cancer diagnosis
article

Imaging Ductal Carcinoma In Situ in the Era of De-Escalation: Role, Limits, and Clinical Implications for Risk-Adapted Management

Francesca Caumo, Gianluca Gatta, Lanfranco Musto, Marcella Buono, Lucia Pilati, Luigi Schiavone, Sighelgaita Rizzo
article en

Abstract

The widespread implementation of population-based mammographic screening has markedly increased the detection of ductal carcinoma in situ (DCIS), without a proportional reduction in breast cancer-specific mortality. This divergence has intensified concerns regarding overdiagnosis and overtreatment and has prompted increasing interest in treatment de-escalation and active surveillance strategies. Breast imaging remains indispensable for DCIS detection, extent assessment, and longitudinal monitoring. However, although imaging features correlate with histopathologic risk factors at the population level, their ability to predict individual biological progression is inherently probabilistic and limited. Overinterpretation of imaging phenotypes as surrogates of invasive destiny risks inappropriate reassurance or unjustified therapeutic escalation, particularly in the context of high-sensitivity modalities that may overestimate disease extent or trigger additional interventions without proven outcome benefits. This review examines the modality-specific roles of mammography, ultrasound, breast magnetic resonance imaging (MRI), contrast-enhanced mammography (CEM), and emerging artificial intelligence (AI) approaches within contemporary DCIS management, with particular attention to their implementation in active surveillance trials such as LORIS, COMET, LORD, and LORETTA. Across modalities, imaging primarily reflects lesion morphology, spatial distribution, and vascular behaviour, and functions most reliably as a risk-filtering and safety-gating instrument aimed at excluding radiologically unsafe scenarios, including occult invasion, underestimated disease extent, or imaging evolution incompatible with continued observation. By delineating both the capabilities and the epistemological limits of imaging, this review proposes a structured clinical decision framework in which imaging supports-but does not independently determine-risk-adapted management. Disciplined integration of imaging into multidisciplinary decision-making is essential to enable safe de-escalation, prevent false reassurance, and align DCIS care with patient-centred and value-based principles.

DiagnosticsVol. 16(5)
Istituto Oncologico Veneto (IT), Azienda Ospedaliera S.Giuseppe Moscati (IT), University of Campania "Luigi Vanvitelli" (IT)
Openalex Percentile: Top 35%
MRI in cancer diagnosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.